Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer

PURPOSE: Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor designed to provide sustained exposure to SN-38 (active metabolite of irinotecan). This phase II study compared EP versus irinotecan as second-line treatment for KRAS-mutant, irinotecan-naïve, metastatic colorectal cancer (m...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Chemother Pharmacol
Autori principali: Lenz, Heinz-Josef, Philip, Philip, Saunders, Mark, Kolevska, Tatjana, Mukherjee, Kalyan, Samuel, Leslie, Bondarde, Shailesh, Dobbs, Tracy, Tagliaferri, Mary, Hoch, Ute, Hannah, Alison L., Berkowitz, Maurice
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6863159/
https://ncbi.nlm.nih.gov/pubmed/29043412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3438-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi